Superworth

Iridex revenue IRIX

Sales by quarter and over the last twelve months, from 2010.

Last 12 months, to Jul 4, 2026
$51.6M
Latest quarter, Q2 FY26
$12.6M
−7% on a year earlier
Fiscal year 2025
$52.7M
+8% on the year before

Iridex's revenue was $51.6M over the twelve months to Jul 4, 2026, up 4% on a year earlier.

In its latest quarter, Q2 FY26, it was $12.6M, down 7% on the same quarter a year before.

Over the five fiscal years to FY2025 it grew 8% a year on average.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2025$52.7M+8%
FY2024$48.7M−6%
FY2023$51.9M−9%
FY2022$57M+6%
FY2021$53.9M+48%
FY2020$36.3M−16%
FY2019$43.4M+2%
FY2018$42.6M+2%
FY2017$41.6M−10%
FY2016$46.2M+11%
FY2015$41.8M−2%
FY2014$42.8M+12%
FY2013$38.3M+13%
FY2012$33.9Mn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q2 FY26$12.6M−7%$51.6M
Q1 FY26$11.8M−1%$52.6M
Q4 FY25$14.7M+16%$52.7M
Q3 FY25$12.5M+8%$50.6M
Q2 FY25$13.6M+7%$49.7M
Q1 FY25$11.9M+1%$48.8M
Q4 FY24$12.7M+2%$48.7M
Q3 FY24$11.6M−10%$48.4M
Q2 FY24$12.6M−2%$49.7M
Q1 FY24$11.8M−14%$49.9M
Q4 FY23$12.5M−18%$51.9M
Q3 FY23$12.8M−12%$54.6M

Against its peers

Companies in Healthcare nearest Iridex's size, closest first, today.

CompanyRevenue, 12 monthsGrowth
IRIXIridex$51.6M+4% a year
NEPHNephros$20.7M+24% a year
ATNMActinium Pharmaceuticalsn/m
APTAlpha Pro Tech$61.9M+6% a year
SPROSpero Therapeutics$47M−3% a year
LFVNLifevantage$182.6M−20% a year
ICCCImmucell$30.7M+8% a year
KEQUKewaunee Scientific$277.2M+5% a year
Peer median$54.5M

Where Iridex ranks

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Iridex

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.